Evidence map›Paper›PMID 35240916›Full record

ArticleCell cycle (Georgetown, Tex.)2022

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with

Luke J Nelson, Kyleen E Castro, Binzhi Xu, Junyi Li, Nguyen B Dinh, Jordan M Thompson, Jordan Woytash, Kevin R Kipp, Olga V Razorenova

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Novel Piperazine Derivatives of Vindoline as Anticancer Agents.International journal of molecular sciences · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Luke J NelsonDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Kyleen E CastroDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Binzhi XuDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Junyi LiDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Nguyen B DinhDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Jordan M ThompsonDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Jordan WoytashDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Kevin R KippBioniz Therapeutics, Irvine, California, USA.
Olga V RazorenovaDepartment of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
University of California, Irvine · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
CARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6M
NRSA Training CoreTL1TR001415 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, HEAD, ELIZABETH · 2015 to 2023
$4.2M
NCATS NIH HHS TL1 TR001415NCATS NIH HHS UL1 TR001414NCI NIH HHS T32 CA009054
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (CC-RCC) remains one of the most deadly forms of kidney cancer despite recent advancements in targeted therapeutics, including tyrosine kinase and immune checkpoint inhibitors. Unfortunately, these therapies have not been able to show better than a 16% complete response rate. In this study we evaluated a cyclin-dependent kinase inhibitor, Dinaciclib, as a potential new targeted therapeutic for CC-RCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAnimalsCell Line, TumorCyclic N-OxidesCyclin-Dependent Kinase Inhibitor ProteinsCyclin-Dependent KinasesFemaleHumansIndolizinesMaleMiceProtein Kinase InhibitorsPyridinium CompoundsSynthetic Lethal MutationsVon Hippel-Lindau Tumor Suppressor ProteinCyclic N-OxidesCyclin-Dependent Kinase Inhibitor ProteinsCyclin-Dependent KinasesdinaciclibIndolizinesProtein Kinase InhibitorsPyridinium CompoundsVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteincyclin-dependent kinaseDinaciclibrenal cell carcinomasynthetic lethalityvon-Hippel Lindau

Identifiers

PMID35240916
PMCPMC9037521
OpenAlexW4214873989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.